{"id":56087,"date":"2023-04-21T14:04:18","date_gmt":"2023-04-21T12:04:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/"},"modified":"2023-04-21T14:04:18","modified_gmt":"2023-04-21T12:04:18","slug":"cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/","title":{"rendered":"CXL Ophthalmics\u2019 CMO To Deliver Plenary Session at 1st Annual International Keratoconus Academy Symposium"},"content":{"rendered":"
\n

\nChief Medical Officer Michael W. Belin, MD, will be a plenary speaker at the event<\/i><\/p>\n

SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, announced today that CMO Michael W. Belin, MD, will present the Plenary Session at the 1st<\/sup> Annual International Keratoconus Academy (IKA) Symposium. The symposium will be held on April 22 and 23 in Scottsdale, AZ, and will convene optometrists, ophthalmologists, and industry experts involved in the management and treatment of keratoconus. In addition to delivering the Plenary Session, Dr. Belin will present during the Best Practices in Keratoconus Diagnostics II session.<\/p>\n

<\/a><\/p>\n

\n\u201cThe first annual IKA symposium on the treatment and management of keratoconus marks an important step in advancing the conversation around this vision-threatening condition,\u201d said Dr. Belin. \u201cThe CXLO team remains dedicated to advancing the EpiSmart\u2122 cross-linking system for earlier intervention and improved outcomes for patients. I look forward to discussing our latest updates and connecting with fellow industry leaders working toward a better future for patients living with keratoconus.\u201d<\/p>\n

\nDr. Belin will lead the following sessions at the 1st<\/sup> Annual IKA Keratoconus Symposium:<\/p>\n

\nSession Title:<\/b> Plenary Session: Tomorrow’s Keratoconus Management Begins Today
\n
Speaker:<\/b> Michael W. Belin, MD and Renato Ambrosio, MD, PhD
\n
Location:<\/b> Scottsdale Marriott at McDowell Mountains, 16770 North Perimeter Drive, Scottsdale, AZ, 85260
\n
Date and Time: <\/b>Saturday, April 22, 2023, 9:00-10:00am MST<\/p>\n

\nSession Title:<\/b> Best Practices in Keratoconus Diagnostics II: Classifying KC Severity, Detecting Progression, and Determining Prognosis
\n
Speaker:<\/b> Michael W. Belin, MD
\n
Location:<\/b> Scottsdale Marriott at McDowell Mountains, 16770 North Perimeter Drive, Scottsdale, AZ, 85260
\n
Date and Time: <\/b>Saturday, April 22, 2023, at 11:30am-12:00pm MST<\/p>\n

\nAbout EpiSmart<\/b><\/p>\n

\nThe patented EpiSmart system, including Ribostat, is designed to optimize cross-linking therapy for keratoconus, allowing minimally-invasive treatment via simultaneous bilateral application of UV light without the need for surgical or chemical disruption of the corneal epithelium. The safety and efficacy of EpiSmart was investigated in a recently concluded 2,258-subject Phase 2 trial, and CXL Ophthalmics is preparing to initiate Phase 3 clinical trials for the treatment of keratoconus with EpiSmart.<\/p>\n

\nAbout<\/b> Keratoconus<\/b><\/p>\n

\nKeratoconus is a bilateral, progressive corneal degenerative disease accompanied by corneal distortion and corneal thinning. In later stages, the cornea takes on a bulging, conical shape, leading to irregular astigmatism that is difficult or impossible to correct and results in loss of functional vision. Typical onset of symptoms occurs in late teens to early twenties but can manifest in children younger than 10 years old. Based on global epidemiological research, estimates of prevalence range from 1.2% in Australia to 4-5% in the Middle East to 8% in Africa, with geographic and ethnic variation. The recent Raine study<\/a>, performed in Australia, showed a prevalence at 1.2%<\/a>, which implies a U.S. prevalence of more than 3 million.<\/p>\n

\nAbout CXL Ophthalmics<\/b><\/p>\n

\nCXLO is developing a minimally-invasive treatment for ectatic corneal disease that can bring early intervention to millions of patients globally. Our EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without disrupting the epithelium, allowing for a rapid return to normal activities.<\/p>\n

\nFor more information, please visit www.cxlophthalmics.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Tara Mulloy
\n
MacDougall Advisors<\/a>
(978) 855-5219
\n
tmulloy@macdougall.bio<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Chief Medical Officer Michael W. Belin, MD, will be a plenary speaker at the event SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, announced today that CMO Michael W. Belin, MD, will present the Plenary Session at the 1st Annual International Keratoconus Academy (IKA) Symposium. The symposium will be … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56087","6":"format-standard","7":"category-industry"},"yoast_head":"\nCXL Ophthalmics\u2019 CMO To Deliver Plenary Session at 1st Annual International Keratoconus Academy Symposium - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CXL Ophthalmics\u2019 CMO To Deliver Plenary Session at 1st Annual International Keratoconus Academy Symposium - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Chief Medical Officer Michael W. Belin, MD, will be a plenary speaker at the event SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, announced today that CMO Michael W. Belin, MD, will present the Plenary Session at the 1st Annual International Keratoconus Academy (IKA) Symposium. The symposium will be ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-21T12:04:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230421005081\/en\/1770491\/21\/CXLOpthalmics_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"CXL Ophthalmics\u2019 CMO To Deliver Plenary Session at 1st Annual International Keratoconus Academy Symposium\",\"datePublished\":\"2023-04-21T12:04:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\\\/\"},\"wordCount\":527,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230421005081\\\/en\\\/1770491\\\/21\\\/CXLOpthalmics_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\\\/\",\"name\":\"CXL Ophthalmics\u2019 CMO To Deliver Plenary Session at 1st Annual International Keratoconus Academy Symposium - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230421005081\\\/en\\\/1770491\\\/21\\\/CXLOpthalmics_logo.jpg\",\"datePublished\":\"2023-04-21T12:04:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230421005081\\\/en\\\/1770491\\\/21\\\/CXLOpthalmics_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230421005081\\\/en\\\/1770491\\\/21\\\/CXLOpthalmics_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CXL Ophthalmics\u2019 CMO To Deliver Plenary Session at 1st Annual International Keratoconus Academy Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CXL Ophthalmics\u2019 CMO To Deliver Plenary Session at 1st Annual International Keratoconus Academy Symposium - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/","og_locale":"en_US","og_type":"article","og_title":"CXL Ophthalmics\u2019 CMO To Deliver Plenary Session at 1st Annual International Keratoconus Academy Symposium - Pharma Trend","og_description":"Chief Medical Officer Michael W. Belin, MD, will be a plenary speaker at the event SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, announced today that CMO Michael W. Belin, MD, will present the Plenary Session at the 1st Annual International Keratoconus Academy (IKA) Symposium. The symposium will be ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-21T12:04:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230421005081\/en\/1770491\/21\/CXLOpthalmics_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"CXL Ophthalmics\u2019 CMO To Deliver Plenary Session at 1st Annual International Keratoconus Academy Symposium","datePublished":"2023-04-21T12:04:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/"},"wordCount":527,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230421005081\/en\/1770491\/21\/CXLOpthalmics_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/","url":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/","name":"CXL Ophthalmics\u2019 CMO To Deliver Plenary Session at 1st Annual International Keratoconus Academy Symposium - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230421005081\/en\/1770491\/21\/CXLOpthalmics_logo.jpg","datePublished":"2023-04-21T12:04:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230421005081\/en\/1770491\/21\/CXLOpthalmics_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230421005081\/en\/1770491\/21\/CXLOpthalmics_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cxl-ophthalmics-cmo-to-deliver-plenary-session-at-1st-annual-international-keratoconus-academy-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"CXL Ophthalmics\u2019 CMO To Deliver Plenary Session at 1st Annual International Keratoconus Academy Symposium"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56087"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56087\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}